Commercializing Your First CGT Product: Value Chain Planning

Commercializing a Cell and Gene Therapy (CGT) product requires a value chain strategy that is fundamentally different from traditional drugs. Since CGTs are often manufactured using patient cells or genetic materials, the value chain must prioritize agility, precision, and complex coordination for each unique dose.

For your first CGT, it's essential to start value chain planning early, as key decisions about manufacturing and site-of-care administration can't wait until commercialization. Be prepared to navigate the complexities of ultra-frozen and cryo-frozen cold storage, and engage partners at least 24 months before launch. Crucially, your strategy must address the impact of reimbursement models—like buy-and-bill versus specialty pharmacy—on treatment centers, and should offer both options to maximize your network. Finally, design the value chain around the individualized patient journey, offering crucial coordination and support to accelerate early uptake.

Dive into the full article for a detailed breakdown of five best practices for CGT value chain planning.